Introduction to AI in Endometrial Cancer Management

The landscape of gynecological oncology is rapidly shifting toward personalized medicine, where the integration of AI in endometrial cancer management is becoming increasingly prominent. Traditionally, the multidisciplinary tumor board (MDT) has served as the gold standard for clinical decision-making. These boards bring together surgeons, oncologists, pathologists, and radiologists to synthesize complex data. However, human decision-making is naturally prone to variability, which can lead to inconsistencies in guideline adherence. Consequently, artificial intelligence and large language models are being evaluated as potential decision-support tools. These technologies aim to enhance the reliability of treatment plans by providing objective, guideline-based recommendations. The primary goal is not to replace the clinician but to offer a digital safety net that ensures every patient receives care aligned with international standards. As we move into an era of data-driven oncology, understanding how these AI tools interact with human expertise is essential. Recent research focuses on the concordance between MDT decisions and AI outputs, specifically examining how deviations from these recommendations impact long-term clinical results. By analyzing these interactions, clinicians can better understand where AI adds the most value in the therapeutic journey.

Methodology and Concordance Analysis

A recent retrospective study analyzed 150 patients with endometrial cancer to evaluate the utility of AI-based recommendations. These recommendations were generated using a large language model configured to follow the ESGO/ESTRO/ESP guidelines. The study specifically focused on standardized clinicopathological inputs, excluding complex molecular classifications to mirror common clinical scenarios. Researchers assessed the level of agreement between the MDT’s final decisions and the AI-generated suggestions. Interestingly, the overall concordance rate reached 76.7%, indicating a significant alignment between human expertise and algorithmic logic. Beyond simple percentages, the study employed Cohen's kappa to evaluate agreement beyond mere chance, which yielded a fair agreement score. This statistical measure highlights that while AI can replicate many standard MDT decisions, there remains a notable portion of cases where human judgment and digital guidelines diverge. These discordant cases provide the most valuable insights into the limitations and strengths of both systems. Furthermore, the researchers categorized these discrepancies into two main directions: relative undertreatment and overtreatment. This differentiation is critical because not all disagreements carry the same clinical weight. Understanding the nature of these deviations allows for a more nuanced application of AI tools in daily oncological practice.

The Clinical Significance of Discordance Direction

When an MDT decision does not align with AI recommendations, the direction of that discordance becomes a primary concern for clinical outcomes. In this research, discordance was not just a binary metric; it was stratified by its potential impact on therapy intensity. Relative undertreatment occurred when the MDT recommended a less intensive regimen than the guideline-based AI suggestion. Conversely, overtreatment involved the human board choosing more aggressive therapy than the standard guidelines necessitated. Identifying these patterns is vital because AI in endometrial cancer protocols often strictly adheres to evidence-based frameworks that MDTs might bypass due to perceived patient frailty or specific institutional preferences. However, the study found that such deviations are not always benign. While clinical experience is invaluable, bypassing standardized guidelines without a clear biological rationale can introduce hidden risks. The analysis suggests that AI can act as a consistent benchmark, highlighting when a treatment plan may be de-escalated beyond what the evidence suggests is safe. Therefore, the focus shifts from whether the AI is "right" to how it can signal potential risks in real-time. This dynamic transforms the AI from a simple calculator into a sophisticated audit tool for multidisciplinary decision-making.

Impact of Undertreatment on Recurrence-Free Survival

The most striking finding of the study pertains to the link between discordance and recurrence-free survival (RFS). Although overall concordance between the MDT and AI was not an independent predictor of survival, the specific direction of discordance was highly significant. Specifically, cases categorized as relative undertreatment were associated with a significantly worse recurrence-free survival. The hazard ratio for these patients reached 1.94, indicating a nearly twofold increase in the risk of recurrence compared to concordant cases. Despite these patients having more favorable baseline characteristics, the event rates in the undertreatment group were substantially higher at 67.9%, compared to only 40.0% in the concordant group. This suggests that treatment de-escalation, even when intended to reduce toxicity or accommodate patient factors, may compromise the curative potential of the intervention. On the other hand, overtreatment did not show a statistically significant association with worse survival outcomes, though it may increase unnecessary side effects. These results underscore the danger of deviating from established guidelines toward less intensive care. By using AI to identify these specific instances of potential undertreatment, clinical teams can pause and re-evaluate their decisions, potentially avoiding adverse outcomes that might otherwise be overlooked in a traditional MDT setting.

AI as a Tool for Guideline Consistency

The implementation of AI in endometrial cancer care offers a unique opportunity to standardize treatment across different centers. In many regions, including India, access to specialized gynecological oncologists can vary, leading to differences in how guidelines are interpreted. AI systems provide a localized version of global expertise, ensuring that the latest ESGO/ESTRO/ESP standards are applied consistently. Because these systems are based on structured logic, they do not suffer from the fatigue or cognitive biases that can affect human boards during long sessions. Moreover, the study demonstrates that AI can effectively flag cases where the MDT might be leaning toward undertreatment. This serves as a critical quality assurance mechanism. By providing a clear, guideline-derived rationale for every recommendation, AI encourages MDT members to document the specific reasons why they might choose to deviate from the standard. This process improves transparency and fosters a culture of evidence-based practice. Furthermore, as molecular classification becomes more integrated into standard care, the complexity of decision-making will only increase. AI tools are uniquely suited to process these multi-omic data points, helping clinicians navigate complex risk-stratification models that are becoming too intricate for manual processing alone.

Future Directions and Integration in Clinical Practice

As we look toward the future, the integration of AI decision-support systems must be handled with care to maintain the human-centric nature of oncology. The study highlights that while AI is excellent at guideline adherence, it cannot yet fully account for the nuanced "art of medicine," such as patient values or psychological readiness. However, its role in preventing clinically significant undertreatment is now undeniable. For Indian oncologists, adopting these tools could bridge the gap between high-volume clinical practice and the meticulous requirements of modern guidelines. Future developments should focus on making these AI models more explainable, allowing doctors to see exactly which data points led to a specific recommendation. Additionally, prospective trials are needed to determine if real-time AI consultation during MDT meetings actually improves survival rates in a live clinical environment. The goal is to create a collaborative ecosystem where human intuition and machine precision work in harmony. Ultimately, the use of AI in endometrial cancer will likely become a standard feature of high-quality care, serving as an essential partner in the fight against gynecological malignancies. By focusing on discordance direction and survival data, we can ensure that these technological advancements lead to tangible improvements in patient longevity and quality of life.

Frequently Asked Questions

How does AI help in the management of endometrial cancer?

AI assists in endometrial cancer management by providing evidence-based treatment recommendations grounded in international guidelines like ESGO. It processes clinicopathological data to suggest optimal surgery, chemotherapy, or radiation plans. By acting as a decision-support tool, AI helps reduce human error and ensures consistency in care, particularly by identifying potential instances of undertreatment that could negatively impact the patient's long-term survival and recurrence risk.

Why is discordance between MDT and AI recommendations important?

Discordance is important because it highlights areas where clinical judgment deviates from standard guidelines. When an MDT recommends less intensive treatment than the AI suggests (undertreatment), research indicates a significantly higher risk of cancer recurrence. Monitoring these discrepancies allows clinical teams to justify their decisions more clearly and avoid unintentional de-escalation of care, which is crucial for maintaining high survival rates in endometrial cancer patients.

Can AI replace the Multidisciplinary Tumor Board (MDT)?

No, AI cannot currently replace the MDT. While AI is superior at processing vast amounts of guideline data and ensuring adherence, it lacks the ability to evaluate nuanced patient factors such as surgical fitness, social support, and personal preferences. Instead, AI should be viewed as a valuable "assistant" that provides an objective benchmark, helping the MDT make more informed, consistent, and safe decisions for their patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. The use of AI in clinical practice should be guided by professional judgment and integrated with comprehensive patient evaluation. Refer to the latest local and national guidelines for clinical practice.

References

Aliyev V et al. Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes. Clin Transl Oncol. 2026 Jul 05. doi: 10.1007/s12094-026-04484-5. PMID: 42402088.

Concin N et al. ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025. Int J Gynecol Cancer. 2025. doi:10.1136/ijgc-2025-006000.

Bosse T et al. AI model accurately predicts endometrial cancer recurrence: the HECTOR study. Nature Medicine. 2024;30(6):1542-1550.